Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/b Clinical trial evaluating VYN201 in healthy volunteers and in vitiligo patients

Next Previous
X
Search
Trial Profile

A Phase 1a/b Clinical trial evaluating VYN201 in healthy volunteers and in vitiligo patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VYN 201 (Primary)
  • Indications Vitiligo
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Sponsors VYNE Therapeutics

    • Most Recent Events

    • 01 May 2024 According to a VYNE Therapeutics media release, abstract reporting Phase 1b data for VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.
    • 29 Feb 2024 According to a VYNE Therapeutics media release, results will be at presented the Foundation's annual symposium held on March 7, 2024 in San Diego.
    • 10 Jan 2024 Results (biomarker data from phase1b) presented in the VYNE Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top